[77–80] Case reports and now recently published preliminary results from the ROAR clinical trial show that metastatic BRAF mutant biliary tract cancers might benefit from BRAF and MEK inhibitors treatment. The gene discussed is BRAF; the disease is biliary tract neoplasm.